CGTX | Cognition Therapeutics, Inc. | [NASD]
Index- P/E- EPS (ttm)-0.95 Insider Own0.30% Shs Outstand29.09M Perf Week-5.09%
Market Cap57.13M Forward P/E- EPS next Y-1.12 Insider Trans0.00% Shs Float19.64M Perf Month15.17%
Income-23.70M PEG- EPS next Q-0.19 Inst Own30.10% Short Float / Ratio0.33% / 0.91 Perf Quarter28.12%
Sales- P/S- EPS this Y-25.80% Inst Trans-1.11% Short Interest0.06M Perf Half Y-17.34%
Book/sh1.23 P/B1.67 EPS next Y-28.70% ROA-46.90% Target Price7.75 Perf Year-17.67%
Cash/sh1.39 P/C1.47 EPS next 5Y- ROE-59.60% 52W Range1.07 - 6.27 Perf YTD-2.38%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-67.30% Beta-
Dividend %- Quick Ratio5.70 Sales past 5Y- Gross Margin- 52W Low91.59% ATR0.20
Employees22 Current Ratio5.70 Sales Q/Q- Oper. Margin- RSI (14)59.57 Volatility13.75% 10.25%
OptionableNo Debt/Eq0.00 EPS Q/Q-24.00% Profit Margin- Rel Volume0.30 Prev Close2.07
ShortableYes LT Debt/Eq0.00 EarningsMay 04 AMC Payout- Avg Volume70.92K Price2.05
Recom1.50 SMA2014.33% SMA5013.32% SMA2006.59% Volume21,744 Change-0.97%
Date Action Analyst Rating Change Price Target Change
Nov-03-21Initiated Oppenheimer Outperform $22
Nov-03-21Initiated B. Riley Securities Buy $27
May-23-23 09:40AM
May-18-23 03:53PM
May-04-23 04:05PM
07:30AM Loading…
May-01-23 07:30AM
Apr-19-23 07:30AM
Apr-12-23 07:30AM
Mar-28-23 07:30AM
Mar-27-23 08:00AM
Mar-23-23 11:03PM
Mar-21-23 08:00AM
Mar-16-23 12:18PM
07:30AM Loading…
Mar-15-23 07:30AM
Mar-07-23 08:00AM
Feb-22-23 08:00AM
Feb-21-23 07:30AM
Feb-20-23 08:50AM
Feb-09-23 08:00AM
Dec-22-22 08:00AM
Dec-21-22 04:05PM
Dec-15-22 08:00AM
Dec-01-22 08:38AM
Nov-28-22 08:00AM
Nov-21-22 08:00AM
Nov-15-22 12:55PM
08:00AM Loading…
Nov-14-22 08:00AM
Nov-10-22 08:00AM
Oct-12-22 08:00AM
Oct-11-22 08:00AM
Sep-29-22 07:30AM
Sep-27-22 07:32AM
Sep-06-22 07:32AM
Aug-11-22 06:56AM
Aug-09-22 07:00AM
Aug-04-22 04:02PM
Aug-03-22 04:05PM
Jul-19-22 08:00AM
Jun-23-22 07:30AM
Jun-08-22 07:30AM
Jun-02-22 04:01PM
May-13-22 07:30AM
May-11-22 07:00AM
May-04-22 05:54PM
May-03-22 08:00AM
May-02-22 11:18AM
Apr-25-22 04:01PM
Apr-06-22 07:30AM
Mar-30-22 07:00AM
Mar-22-22 08:00AM
Mar-10-22 07:30AM
Mar-08-22 08:00AM
Feb-08-22 07:30AM
Jan-10-22 07:30AM
Jan-08-22 07:01AM
Jan-04-22 07:30AM
Dec-21-21 07:30AM
Nov-30-21 07:30AM
Nov-18-21 08:00AM
Nov-15-21 07:30AM
Nov-03-21 08:00AM
Nov-02-21 06:00AM
Oct-18-21 10:59AM
Oct-15-21 10:26AM
Oct-12-21 11:23AM
Oct-08-21 05:50PM
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex for the treatment of Alzheimer's disease. The company is also developing COG0201 SHINE, a randomized double-blind and placebo-controlled for mild-to-moderate AD and is in phase II clinical trial. Its product pipeline also includes CT2168 for Synucleinopathies; and CT2074 for dry age-related macular degeneration. The company was incorporated in 2007 and is headquartered in Purchase, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RICHSTONE ELLEN BDirectorNov 29Buy2.6510,00026,55010,000Nov 29 04:57 PM
Ricciardi LisaCEO & PresidentNov 15Buy1.3012,00015,60024,500Nov 16 08:31 AM
Wallace PeggyDirectorNov 15Buy1.2012,50015,00037,961Nov 16 08:30 AM